TP53-Mutated AML/MDS Patient Outcomes After Allogeneic Transplantation

66 patient records from a multi-center retrospective study of TP53-mutated acute myeloid leukemia or myelodysplastic syndromes who underwent allogeneic hematopoietic stem cell transplantation. The dataset includes endpoints for overall survival, progression-free survival, cumulative incidence of relapse, and non-relapse mortality. The study was authored by Yao Sun and last updated in May 2026.

Use Cases

• Predicting overall survival based on genetic profiles and clinical characteristics mentioned in the description
• Analyzing the cumulative incidence of relapse following transplantation using the provided endpoints
• Modeling progression-free survival for TP53-mutated AML/MDS patients
• Investigating the impact of non-relapse mortality on transplant outcomes

Strengths

• 66 patient records from a multi-center study
• Includes four key clinical endpoints: OS, PFS, CIR, and NRM

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is 20.8 KB, indicating a very limited scope

Provenance

Source

figshare

Collection Method

Multi-center retrospective study analysis

Freshness

Last updated 2026-05-06 00:10:09